5-mC DNA methylation in neurodevelopment: from molecular mechanisms to therapeutic implications.

This review looks at how a specific type of gene regulation called DNA methylation affects brain development and autism-related conditions. The research shows that changes in this process contribute to autism, fragile X syndrome, Rett syndrome, and epilepsy. In autism, these changes might help with diagnosis. The study suggests this area could lead to new ways to diagnose and treat these conditions, though there are still technical challenges to overcome.

This review examines the role of 5-mC DNA methylation in neurodevelopment and neurological disorders. 5-mC methylation regulates neural stem cell differentiation and neuronal maturation through specific proteins (DNMTs and MBD proteins). The review identifies disrupted methylation patterns in several neurodevelopmental conditions: autism spectrum disorder shows altered methylation in SHANK family genes and genome-wide changes that may serve as diagnostic biomarkers; fragile X syndrome involves increased FMR1 gene promoter methylation leading to protein deficiency; Rett syndrome features disrupted methylation-dependent transcriptional regulation due to MECP2 mutations; and epilepsy shows methylation abnormalities in epilepsy-related genes affecting treatment responses. The authors highlight significant challenges including tissue specificity, technical detection limitations, and therapeutic targeting difficulties, while emphasizing potential for methylation-based diagnostics and treatments.

DNA methylation patterns show promise as diagnostic biomarkers for neurodevelopmental disorders, particularly autism. Understanding methylation mechanisms could enable novel therapeutic strategies targeting epigenetic modifications. However, technical challenges in detection and therapeutic targeting must be addressed before clinical translation.

The review identifies significant challenges including tissue specificity issues, technical limitations in methylation detection methods, and difficulties in therapeutic targeting. As a review paper, findings are synthesized from existing literature rather than presenting new experimental data.

5-mC DNA methylation is a fundamental epigenetic modification that plays a crucial role in neurodevelopment and neurological disorders. This review synthesizes the current understanding of 5-mC DNA methylation in neural system development and its implications in neurodevelopmental disorders. During normal neural development, 5-mC methylation precisely regulates neural stem cell differentiation and neuronal maturation through DNA methyltransferases (DNMTs) and methyl-CpG-binding domain (MBD) proteins. Disruption of these methylation patterns contributes to various neurodevelopmental disorders.

In autism spectrum disorder (ASD), altered methylation patterns in specific genes like SHANK family and genome-wide methylation changes have been identified as potential diagnostic biomarkers. In fragile X syndrome, CGG trinucleotide repeat expansion increases methylation of the FMR1 gene promoter, leading to FMRP protein deficiency. Rett syndrome, primarily caused by MECP2 mutations, involves disrupted methylation-dependent transcriptional regulation. In epilepsy, DNA methylation abnormalities affect multiple epilepsy-related genes and may influence treatment responses to ketogenic diets.

Despite these advances, the field faces significant challenges including tissue specificity issues, technical limitations in methylation detection, and therapeutic targeting difficulties. This review also discusses future perspectives, emphasizing the potential of DNA methylation as a therapeutic target and biomarker for neurodevelopmental disorders. Understanding these methylation mechanisms could lead to novel diagnostic tools and therapeutic strategies for various neurological conditions.